FFO
UNCY icon

Fortitude Family Office’s Unicycive Therapeutics UNCY Stock Holding History

Fortitude Family Office’s Portfolio UNCY Stock Details UNCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$352 Hold
75
– – ﹤0.01% 2030
2026
Q1 		$494 Buy
+75
New +$491 ﹤0.01% 1734
2025
Q4 		– Sell
-107
Closed -$467 – 2132
2025
Q3 		$467 Buy
+107
New +$466 ﹤0.01% 1835

Other funds holding UNCY

CPIG
Chicago Partners Investment Group Chicago, Illinois $5B AUM 26.84% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
TFM
TFC Financial Management Boston, Massachusetts $902M AUM 21.74% 1-Year Est. Return
SCM
Sterling Capital Management Charlotte, North Carolina $5.9B AUM 29.63% 1-Year Est. Return
BWL
Bogart Wealth LLC Mclean, Virginia $2.92B AUM 23.85% 1-Year Est. Return

Fortitude Family Office's UNCY Position: Q2 2026 in Review

Fortitude Family Office held its Unicycive Therapeutics (UNCY) position steady in Q2 2026 at 75 shares worth $352. The position accounts for ﹤0.01% of the portfolio, ranked #2030.

Fortitude Family Office first reported a position in UNCY in Q3 2025 and has held it in 3 quarters since. The position peaked at $494 in Q1 2026. 10 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

  • Fortitude Family Office held 75 shares of Unicycive Therapeutics worth $352 as of Q2 2026.
  • Fortitude Family Office left its Unicycive Therapeutics share count unchanged in Q2 2026.
  • Unicycive Therapeutics made up ﹤0.01% of Fortitude Family Office's portfolio in Q2 2026, its #2030 holding.
  • Fortitude Family Office first reported a position in Unicycive Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Fortitude Family Office's Unicycive Therapeutics position peaked at $494 in Q1 2026.
  • 10 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on Fortitude Family Office's 13F filing for Q2 2026, filed 20 Jul 2026.